These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22891561)

  • 1. [Antitachyarrhythmic interventions of implantable cardioverter-defibrillator in primary and secondary sudden cardiac death prevention patients].
    Piekarz J; Rydlewska A; Majewski J; Lelakowski J
    Pol Merkur Lekarski; 2012 Jun; 32(192):368-73. PubMed ID: 22891561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
    Zaman S; Sivagangabalan G; Chik W; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
    J Interv Card Electrophysiol; 2014 Dec; 41(3):195-202. PubMed ID: 25267274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications.
    Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R
    Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients.
    Kleemann T; Strauss M; Kouraki K; Zahn R
    Europace; 2015 Jul; 17(7):1068-75. PubMed ID: 25687746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Factors predisposing to the reprogramming of implantable cardioverter-defibrillators and the causes of changes in pharmacotherapy in patients with dilated cardiomyopathy for primary prevention of sudden cardiac death].
    Pudło J; Liszniański P; Senderek T; Lelakowska-Pieła M; Lelakowski J; Nowak J
    Pol Merkur Lekarski; 2015 Aug; 39(230):86-90. PubMed ID: 26319381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Negative result of microvolt T-wave alternans test is helpful in scheduling the order of cardioverter-defibrillator implantation in primary prevention of sudden cardiac death in individuals with the left ventricular systolic dysfunction].
    Daniłowicz-Szymanowicz L; Szwoch M; Raczak J; Raczak G
    Pol Merkur Lekarski; 2012 Oct; 33(196):193-7. PubMed ID: 23272605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest.
    Backenköhler U; Erdogan A; Steen-Mueller MK; Kuhlmann C; Most A; Schaefer C; Stertmann W; Waas W; Tillmanns H; Waldecker B
    J Cardiovasc Electrophysiol; 2005 May; 16(5):478-82. PubMed ID: 15877617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-pharmacologic prevention of sudden cardiac death].
    Jurkovicová O; Cagán S
    Bratisl Lek Listy; 1997; 98(7-8):423-39. PubMed ID: 9471337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators.
    Betensky BP; Tschabrunn CM; Zado ES; Goldberg LR; Marchlinski FE; Garcia FC; Cooper JM
    Heart Rhythm; 2012 Jun; 9(6):884-91. PubMed ID: 22338670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients.
    Chen X; Shenasa M; Borggrefe M; Block M; Hindricks G; Martinez-Rubio A; Haverkamp W; Willems S; Böcker D; Mäkijärvi M
    Eur Heart J; 1994 Jan; 15(1):76-82. PubMed ID: 8174587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
    Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
    Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.